Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123851 · ClinicalTrials.gov registry record · Phase 2
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00123851: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT00123851 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00123851, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This trial is designed to investigate the safety, tolerability and the effectiveness when OSI-774 (tarceva) is combined with oxaliplatin and capecitabine in treating patients with metastatic colorectal cancer.
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Tarceva (OSI-774)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
What the finished NCT00123851 record still lists
NCT00123851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT00123851 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00123851 about?
NCT00123851 is a clinical study titled "Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer". This trial is designed to investigate the safety, tolerability and the effectiveness when OSI-774 (tarceva) is combined with oxaliplatin and capecitabine in treating patients with metastatic colorectal cancer.
What is the current status of trial NCT00123851?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2003-03. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00123851?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Tarceva (OSI-774) (DRUG).
Who is sponsoring clinical trial NCT00123851?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00123851's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia